What is it about?
Healthcare is not the same for everyone. Underrepresented populations have lot of hurdles to access approved treatments. The latest medicine for Alzheimer's highlights the health disparities in research representation and access to care.
Featured Image
Photo by diGital Sennin on Unsplash
Why is it important?
We outline the racial and socioeconomic health disparities in aducanumab treatment: 1) Disparities in the risk of Alzheimer’s disease (AD), 2) Limited participation from under-represented groups in AD trials raising concerns about the generalizability of the results, 3) Questionable applicability of the amyloid hypothesis in groups under-represented in AD research, and 4) Aducanumab’s initial sticker price that unfairly singled out those with less means.
Perspectives
Minorities are at high risk of Alzheimer's. Yet they are underrepresented in research studies. This needs to change.
Sanjana Padala
Vanderbilt University
Read the Original
This page is a summary of: Under-Represented Populations Left Out of Alzheimer’s Disease Treatment with Aducanumab: Commentary on Ethics, Journal of Alzheimer s Disease Reports, June 2022, IOS Press,
DOI: 10.3233/adr-220023.
You can read the full text:
Contributors
The following have contributed to this page
